Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

NCT02023112 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: ABT-450/r/ABT-267
DRUG: Ribavirin

Sponsor

AbbVie